Fidaxomicin: first-in-class macrocyclic antibiotic

References

• Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N. Engl. J. Med.330, 257–262 (1994).
   PubMed Web of Science ®Google Scholar
• Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J. Infect.61, 1–8 (2010).
   PubMed Web of Science ®Google Scholar
• McGowan AP, Lalayiannis LC, Sharma JB et al. Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J. Hosp. Infect.77, 11–15 (2011).
   PubMedGoogle Scholar
• Blanckaert K, Coignard B, Grandbastien B et al. Update on Clostridium difficile infections. Rev. Med. Interne.29(3), 209–214 (2008).
   PubMedGoogle Scholar
• Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med.346, 334–339 (2002).
   PubMed Web of Science ®Google Scholar
• Gerding DN, Olson MM, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch. Intern. Med.146, 95–100 (1986).
   PubMed Web of Science ®Google Scholar
• Marciniak C, Chen D, Stein AC, Semik PE. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch. Phys. Med. Rehabil.87, 1086–1090 (2006).
   PubMed Web of Science ®Google Scholar
• Riggs MM, Sethi AK, Zabarsky TF et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis.45, 992–998 (2007).
   PubMed Web of Science ®Google Scholar
• Gerding DN. Global epidemiology of Clostridium difficile infection in 2010. Infect. Control Hosp. Epidemiol.31(Suppl. 1), S32–S34 (2010).
   PubMed Web of Science ®Google Scholar
• Gould LH, Lumgago B. Clostridium difficile in food and domestic animals: a new foodborne pathogen? Clin. Infect. Dis.51(5), 577–582 (2010).
   PubMed Web of Science ®Google Scholar
• Rupnik M. Clostridium difficile: (re)emergence of zoonotic potential. Clin. Infect. Dis.51(5), 583–584 (2010).
   PubMedGoogle Scholar
• Gerding DN. Disease associated with Clostridium difficile infection. Ann. Intern. Med.110, 255–257 (1989).
   PubMed Web of Science ®Google Scholar
• McFarland LV, Stamm WE. Review of Clostridium difficile-associated diseases. Am. J. Infect. Control14, 99–109 (1986).
   PubMedGoogle Scholar
• Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol.23, 653–659 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol.31(5), 431–455 (2010).
   PubMed Web of Science ®Google Scholar
• Roda PI. Clostridium difficile colitis induced by cytarabine. Am. J. Clin. Oncol.10, 451–452 (1987).
   PubMedGoogle Scholar
• Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin. Infect. Dis.17, 109–113 (1993).
   PubMed Web of Science ®Google Scholar
• Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J. Infect. Dis.143, 42–50 (1981).
   PubMed Web of Science ®Google Scholar
• Collins MD, Lawson PA, Willems A et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int. J. Syst. Bacteriol.44, 812–826 (1994).
   PubMedGoogle Scholar
• Tannock GW, Munro K, Taylor C et al. A new macrocycle antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology156, 11, 3354–3359 (2010).
   Google Scholar
• Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N. Engl. J. Med.353, 2442–2449 (2005).
   PubMed Web of Science ®Google Scholar
• Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol.26, 273–280 (2005).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med.353, 2433–2441 (2005).
   PubMed Web of Science ®Google Scholar
• Pearson A. Historical and changing epidemiology of healthcare-associated infections. J. Hosp. Infect.73, 296–304 (2009).
   PubMedGoogle Scholar
• Warny M, Pepin J, Fang A et al. Toxin producton by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet366, 1079–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr. Opin. Gastroenterol.23(1), 4–9 (2007).
   PubMed Web of Science ®Google Scholar
• Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut57, 850–860 (2008).
   PubMed Web of Science ®Google Scholar
• Spigaglia P, Mastriantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J. Clin. Microbiol.40(9), 3470–3475 (2002).
   PubMed Web of Science ®Google Scholar
• CDC. Severe Clostridium difficile-associated disease in populations previously at low risk – four states, 2005. MMWR Morb. Mortal. Wkly Rep.54, 1201–1205 (2005).
   PubMedGoogle Scholar
• Rouphael NG, O’Donnell JA, Bhatnagar J et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol.198(6), 635 e1–e6 (2008).
   PubMedGoogle Scholar
• Maroo S, LaMont JT. Recurrent Clostridium difficile. Gastroenterology130, 1311–1316 (2006).
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis.40, 1586–1590 (2005).
   PubMed Web of Science ®Google Scholar
• Pépin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis.40, 1591–1597 (2005).
   PubMed Web of Science ®Google Scholar
• Pépin J, Valiquette L, Gagnon S et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol.102, 2781–2788 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infec. Control Hosp. Epidemiol.28(11), 1219–1227 (2007).
   PubMed Web of Science ®Google Scholar
• Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis.34, 346–353 (2002).
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol.30(1), 57–66 (2009).
   PubMed Web of Science ®Google Scholar
• Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J. Antibiot.28, 247–252 (1975).
   PubMed Web of Science ®Google Scholar
• Theriault RJ, Karwowski JP, Jackson M et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. J. Antibiot.40, 567–574 (1987).
   PubMed Web of Science ®Google Scholar
• Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert. Opin. Investig. Drugs17, 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr. Opin. Investig. Drugs8, 168–173 (2007).
   PubMed Web of Science ®Google Scholar
• Swanson RN, Hardy DJ, Shipkowitz NL et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother.35, 1108–1111 (1991).
   PubMed Web of Science ®Google Scholar
• Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother.48, 2280–2282 (2004).
   PubMed Web of Science ®Google Scholar
• Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes; III. Mechanism of action. J. Antibiot.38(7), 543–549 (1975).
   Google Scholar
• Sears P, Babakhani F, Citron DM et al. Typing and susceptibility of bacterial isolates from the OPT-80 (PAR-101) Phase 2A study for C. difficile-associated diarrhea. Presented at: 9th Biennial Congress of the Anaerobe Society of the Americas, Long Beach, CA, USA, 24–27 June 2008 (Poster).
   Google Scholar
• Seddon J, Sears P. Preliminary OPT-80 mode of action studies. Optimer Pharmaceuticals, Inc. Report Number BIO090203A (2003).
   Google Scholar
• Osburne M, Sonenshein A. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J. Virol.33, 945–953 (1980).
   PubMed Web of Science ®Google Scholar
• Sonenshein A, Alexander H, Rothstein D, Fisher S. Lipiarmycin resistant ribonucleic acid polymerase mutants of Bacillus subtilis. J. Bacteriol.132, 73–79 (1977).
   PubMed Web of Science ®Google Scholar
• Coronelli C, White RJ, Lancini GC et al. A new antibiotic from Actinoplanes; II. Isolation, chemical, biological and biochemical characterization. J. Antibiot.28(4), 253–259 (1975).
   PubMed Web of Science ®Google Scholar
• Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother.48(11), 4430–4434 (2004).
   PubMed Web of Science ®Google Scholar
• Louie TJ, Emery J, Krulicki W et al. 2009 OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother.53, 261–262 (2009).
   PubMed Web of Science ®Google Scholar
• Babakhani F, Seddon, J, Robert N et al. Effect of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) vs. Clostridium difficile. Antimicrob. Agents Chemother.54, 2674–2676 (2010).
   PubMedGoogle Scholar
• Sears P, Louie TJ, Mullane KM et al. Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Louie T, Miller M, Donskey C et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a Phase 2 trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother.53(1), 223–228 (2009).
   PubMed Web of Science ®Google Scholar
• Okumu F, Walsh RB, Sears P, Shue YK. Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, 30 October–2 November 2004.
   Google Scholar
• Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med.364, 422–431 (2011).
   PubMed Web of Science ®Google Scholar
• Crook D, Weiss K, Cornely OA et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin. Programs and Abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria (2010) (Abstract LB 2401).
   Google Scholar
• Nelson RL. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev.3, CD004610 (2007).
   Google Scholar
• Shue YK, Sears PS, Shangle S et al. Safety, tolerance and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother.52, 1391–1395 (2008).
   PubMed Web of Science ®Google Scholar
• Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Programs and Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (2009) (Abstract L1-1640).
   Google Scholar
• Nerandzic MM, Mullane K, Miller M et al. Acquisiton and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin (FDX) versus vancomycin (VAN) for Clostridium difficile infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis.5(9), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Louie TJ, Peppen J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis.43, 411–420 (2006).
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis.43, 421–427 (2006).
   PubMed Web of Science ®Google Scholar
• Louie T, Gerson M, Grimard D et al. Results of a Phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA, 17–20 September 2007 (Poster 3826).
   Google Scholar
• Gerding D. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin. Infect. Dis.25(Suppl. 2), S206–S210 (1997).
   PubMedGoogle Scholar
• McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg. Infect. Dis.12(3), 409–415 (2006).
   PubMed Web of Science ®Google Scholar